Evidence map›Paper›PMID 27619223›Full record

ArticleWiener klinische Wochenschrift2016

Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Christian Geltner, Peter Errhalt, Bernhard Baumgartner, Gerhard Ambrosch, Barbara Machan, Josef Eckmayr, Thomas Klikovits, Mir Alireza Hoda, Helmut Popper, Walter Klepetko and 1 more

Open access · hybridAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Malignant mesothelioma: health care awareness and preparedness.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Malignant pleural mesothelioma: predictors and staging.Annals of translational medicine · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Christian GeltnerDepartment of Pulmonology, Klinikum Klagenfurt, Feschnigstraße 11, Klagenfurt, Austria. christian@geltner.at.
Peter ErrhaltDepartment of Pulmonology, University Clinic Krems, Krems, Austria.
Bernhard BaumgartnerDepartment of Pulmonology, Landeskrankenhaus Vöklabruck, Vöklabruck, Austria.
Gerhard AmbroschDepartment of Pulmonology, Landeskrankenhaus Graz Südwest, Graz, Austria.
Barbara MachanRehabilitation Center Tobelbad, Allgemeine Unfallversicherungsanstalt, Tobelbad, Austria.
Josef EckmayrDepartment of Pulmonology, Landeskrankenhaus Wels, Wels, Austria.
Thomas KlikovitsDivision of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Mir Alireza HodaDivision of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Helmut PopperDepartment of Pathology, Medical University Graz, Graz, Austria.
Walter KlepetkoDivision of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Austrian Mesothelioma Interest Group (AMIG)
Comprehensive Cancer Center Vienna · ATKlinikum Klagenfurt · ATLandeskrankenhaus Feldkirch · ATMedical University of Graz · ATBarmherzige Schwestern vom heiligen Kreuz · ATUniversitätsklinikum Krems · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma is a rare malignant disease that in the majority of cases is associated with asbestos exposure. The incidence in Europe is about 20 per million inhabitants and it is increasing worldwide. Initial symptoms are shortness of breath, pleural effusion, cough, and chest pain. The typical growth pattern is along the pleural surface; however, infiltration of the lung and/or mediastinal and chest wall structures can occur in a more advanced stage. Ultimately, distant metastases outside the chest can result. Several histological subtypes of pleural mesothelioma exist, which must be differentiated from either benign diseases or metastases in the pleural space by other tumor entities. This differential diagnosis can be very difficult and a large panel of immunohistochemical markers is required to establish the exact diagnosis. The standard procedure for confirming the disease and obtaining sufficient tissue for the diagnosis is videothoracoscopy. Full thickness biopsies are required, while transthoracic needle puncture of pleural fluid or tissue is considered to be insufficient for a cytological diagnosis. Complete and detailed staging is mandatory for categorization of the disease as well as for therapeutic decision making.

Indexed as

Diagnosis, DifferentialDiagnostic ImagingEvidence-Based MedicineHumansMedical OncologyMesotheliomaNeoplasm StagingPleural Effusion, MalignantPleural NeoplasmsPractice Guidelines as TopicPrevalenceRisk FactorsDiagnosisEpidemiologyMalignant pleural mesotheliomaPathologyStaging

Identifiers

PMID27619223
PMCPMC5033998
OpenAlexW2519565926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.